益气养阴汤联合厄洛替尼治疗中晚期肺腺癌临床研究

目的 观察益气养阴汤联合厄洛替尼治疗中晚期肺腺癌的疗效。方法 将60例中晚期肺腺癌患者按照随机数字表法分为治疗组和对照组，每组30例。治疗组采用益气养阴中药联合厄洛替尼治疗，对照组仅服用厄洛替尼。观察并比较两组实体瘤疗效及基于中医证候评分的疗效；治疗前后分别采用卡氏功能状态（Karnofsky performance status, KPS）量表评价患者的生存质量。结果 治疗组患者实体瘤疗效和基于气阴两虚证积分的疗效均明显优于对照组（P＜0.05）。与治疗前比较，治疗组患者治疗后KPS评分显著升高（P＜0.05），对照组患者治疗后KPS评分略有降低（P＞0.05），治疗组患者KPS评分升高程度显著大于对照组（P＜0.05）。结论 益气养阴汤联合厄洛替尼可明显提高中晚期肺腺癌患者的生存质量和实体瘤疗效，减轻气阴两虚证的临床表现。

Clinical Effect of Yiqi Yangyin Decoction Combined with Erlotinib in Treatment of Advanced Lung Adenocarcinoma

Objective To investigate the clinical effect of Yiqi Yangyin Decoction combined with erlotinib in the treatment of advanced lung adenocarcinoma. Methods A total of 60 patients with advanced lung adenocarcinoma were divided into treatment group and control group using a random number table, with 30 patients in each group. The patients in the treatment group were given Yiqi Yangyin Decoction combined with erlotinib, and those in the control group were given erlotinib alone. The two groups were compared in terms of the outcome of solid tumor and the clinical outcome based on traditional Chinese medicine (TCM) syndrome score, and Karnofsky performance scale (KPS) was used to evaluate patients'' quality of life before and after treatment. Results Compared with the control group, the treatment group had significantly better outcome of solid tumor and clinical outcome based on the score of deficiency of both Qi and Yin (P<0.05). The treatment group had a significant increase in KPS score after treatment (P<0.05), while the control group had a slight reduction in KPS score after treatment (P>0.05); the treatment group had a significantly greater increase in KPS score than the control group (P<0.05). Conclusion In patients with advanced lung adenocarcinoma, Yiqi Yangyin Decoction combined with erlotinib can significantly improve their quality of life and the outcome of solid tumor and alleviate the clinical manifestations of the syndrome of deficiency of both Qi and Yin.